USFDA issues two observations for Cipla's Indore plant
Following a Pre-Approval Inspection
Cipla announced that the United States Food and Drug Administration (USFDA) conducted a Pre-Approval Inspection (PAI) at the Company's Indore plant from 27 June 2022 to 1 July 2022. The Company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at the said plant. There is no data integrity observation.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jul 05 2022 | 9:49 AM IST